Desferal (deferoxamine)

Manufacturer:
Novartis
Route of Administration: 
Subcutaneous, Intravenous
Site of Care:
Outpatient
Website: 
    Enrollment Forms:
    Synergen Prescription Form

    Approved Indication:

    • as an adjunct to standard measures for the treatment of acute iron intoxication
    • treatment of transfusional iron overload in patients with chronic anemia

    Conditions:

    • Sickle Cell Disease
    • Anemia